Reneo Pharma appoints Ashley F. Hall as Chief Development Officer

OnKure Therapeutics, Inc.

Hall previously CDO at Esperion; oversaw regulatory for NEXLETOL, NEXLIZET, and REPATHA.
Base salary $420,000, bonus up to 40%, housing reimbursement up to $5,000/month.
Relocation assistance of $150,000 if relocated within 18 months.
Equity inducement: option for 180,000 shares (4-yr vest) and RSU for 30,000 shares (vests on first NDA/MAA).
Severance: 9 months base/COBRA; on change in control 12 months plus full equity acceleration.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ashley F. Hall

Chief Development Officer

OKUR · OnKure Therapeutics, Inc.

Effective: 2021-10-11
Filed: October 12, 2021, 7:59 PM ET

On October 11, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) announced the appointment of Ashley F. Hall, J.D., as the Chief Development Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ashley F. Hall was appointed as Chief Development Officer at OnKure Therapeutics, Inc..

Action: appointed
Role: Chief Development Officer

Exact text from the filing

On October 11, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) announced the appointment of Ashley F. Hall, J.D., as the Chief Development Officer of the Company.

View on SEC.gov

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-296205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.